Group items tagged

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. Cancer. 2009 Nov 13. [Epub ahead of print] PMID: 19918922 DOI: 10.1002/cncr.24749 METHODS: Patients with bone metastases treated with bisphosphonates were enrolled into this single-arm phase 2 study. Patients received 10,000 IU of vitamin D3 and 1000 mg of calcium supplementation each day for 4 months. The effect of this treatment on palliation, bone resorption markers, calcium metabolism, and toxicity were evaluated at baseline and monthly thereafter. CONCLUSIONS: Daily doses of 10,000 IU vitamin D3 for 4 months appear safe in patients without comorbid conditions causing hypersensitivity to vitamin D. Treatment reduced inappropriately elevated parathyroid hormone levels, presumably caused by long-term bisphosphonate use. There did not appear to be a significant palliative benefit nor any significant change in bone resorption. Cancer 2010. © 2009 American Cancer Society.

Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Eur Urol. 2005 Apr;47(4):449-54; discussion 454-5. Epub 2005 Jan 19. PMID: 15774240 doi:10.1016/j.eururo.2004.12.001

Maintaining adequate levels of vitamin D during winter months requires a daily dose of 20 micrograms, four times the current recommended dose, says a new study. The study, led by Susan Sullivan from the University of Maine, has important implications for ongoing consultations on vitamin D recommendations, with the current level of five micrograms (200 International Units) seen by many as insufficient.

ScienceDaily (Feb. 8, 2006) - Vitamin D can inhibit the spread of prostate cancer cells by limiting the activity of two specific enzymes, University of Rochester Medical Center scientists report. \n\nThe finding means that vitamin D could provide beneficial treatment to prostate cancer patients with high levels of the enzymes, the scientists said.\n

Sept. 12, 2006 -- Getting the recommended intake of vitamin D from diet, supplements, or even the sun may cut your risk of pancreatic cancer. The results of two large, long-term surveys show that adults who got 300 IU to 449 IU (international units) per day had a 43% lower risk of pancreatic cancer. The recommended intake of vitamin D for adults aged 51-70 is 400 IU per day.

"The clinical potential for a liver-protective supplement in cancer care is significant, as I've observed in many years of integrative medical practice," writes Dr. Keith Block, ICT editor. "Several chemotherapy drugs, as well as many of the other drugs cancer patients take, have extremely problematic liver toxicities. With this exclusive edition, the scientific community will have a resource to guide and inspire further research on this very interesting herbal medicine."

Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration.\nYeom CH, Jung GC, Song KJ.\nJ Korean Med Sci. 2007 Feb;22(1):7-11.\nPMID: 17297243

(WASHINGTON, February 3, 2009) - Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer. However, a new study suggests that some components of green tea may counteract the anticancer effects of one cancer therapy, bortezomib (Velcade®), and may be contraindicated for patients taking this medicine to ensure its maximum therapeutic benefit. This study is being prepublished online today in Blood, the official journal of the American Society of Hematology.

Grant WB, Garland CF, Gorham ED. An estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day. Recent Results Cancer Res. 2007;174:225-34. PMID: 17302200 [PubMed - in process]

Broccoli, cabbage, cauliflower, brussels sprouts, kale and kohlrabi - this family of cruciferous vegetables is naturally rich in indole-3-carbinol (I3C), a compound that is quickly becoming recognized as one of the most powerful cancer-fighting compounds that we know of.

Beta glucan is a scientifically proven biological defense modifier (BDM) that nutritionally potentiates and modulates the immune response. As a supplement, after swallowing orally, Beta glucan is ingested primarily through macrophage and dendritic immune cells, to nutritionally and safely yield, through immune response potentiation and modulation, in many instances various therapeutic healing effects generated by the immune cells.  For many years Glucans have been investigated (History) for these immune enhancing properties, particularly their ability to activate macrophage immune cells and NK-Cells, plus in turn, the T-Cells, and B-Cells including selected cytokines and complement. 

β-Glucans (or beta-glucans) are polysaccharides of D-glucose monomers linked by glycosidic bonds. They occur most commonly as cellulose in plants and trees, the bran of cereal grains, the cell wall of baker's yeast, certain types of fungi, and many kinds of mushrooms and bacteria. Some forms of beta glucans are useful in human nutrition as texturing agents and as soluble fiber supplements, but problematic in brewing as excessive levels make the wort too viscous. Yeast derived beta glucans are notable for their immunomodulatory function

Coriolus versicolor is a mushroom of the Basidiomycetes class. It was used initially in Traditional Chinese medicine as a tonic, but recent studies suggest that it has immunostimulant and anti-tumor properties. Polysaccharide-K (PSK), a proprietary product derived from Coriolus, was developed for cancer treatment in Japan. When used as an adjuvant, PSK appears to improve survival rates in patients with gastric (1) (2) and colorectal (3) (4) (5) cancers. Other Coriolus extracts, such as polysaccharide-peptide (PSP) and VPS, are available as dietary supplements. When used in conjunction with chemotherapy, PSP may benefit patients with advanced non-small cell lung cancer (7). Other clinical studies using Coriolus extract alone or in combination with other botanicals also suggest positive immunomodulatory effects (8) (9). However, studies on breast cancer (10), hepatocellular carcinoma (11), and leukemia (12) produced mixed results. A hot water extract of Coriolus, VPS, was found to enhance development of large intestinal tumors in mice (21). Coriolus extracts are generally well tolerated but minor adverse effects have been reported. Many over-the-counter Coriolus products are not standardized, making it difficult to compare potency between brands. It is also unclear if PSK, PSP and other Coriolus extracts have comparable effects.

f you are looking for Sodium Dichloroacetate or Miracle Mineral Supplement kit, then you are at the right place. We ship worldwide, also to the United States. We offer on-demand chemical compounds meeting the highest quality and safety standards. We support secure payment and 24 hours order processing as well as retail and bulk orders. Each batch comes with an individual chemical analysi

What is VITAL? The VITamin D and OmegA-3 TriaL (VITAL) is a research study in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D (about 2000 IU) or fish oil (about 1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. Recruitment for the study will begin in January 2010.

Derived from the cap and stem of the mushroom. The active constituent is thought to be a beta-glucan polysaccharide. The whole mushroom is used primarily as a dietary element, but extracts and supplements are sold as immune stimulants for patients with HIV or cancer. While no adverse effects have been reported, some studies reveal a hypoglycemic effect following administration of maitake extract (9) (12). Maitake was shown to enhance bone marrow colony formation, reduce doxorubicin toxicity in vitro (11), and to inhibit tumor metastasis

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features. C. M. Rudin, D. Lansey, K. D. Burroughs, L. M. Hales, J. R. Neefe, P. S. Reddy and P. L. Hallenbeck Johns Hopkins Univ, Baltimore, MD; Neotropix, Inc., Malvern, PA. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 18014 © 2007 American Society of Clinical Oncology. Conclusions: NTX-010 is a novel first-in-class anticancer virus with selective tropism for tumors with neuroendocrine features. This is the first anticancer virus given intravenously with documented selective intratumoral infection and replication. Administration was well tolerated. Safety data and viral kinetics will be presented.

Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, Al-Shabanah OA, Sayed-Ahmed MM. World J Gastroenterol. 2009 Mar 21;15(11):1373-80. PMID: 19294768

ScienceDaily (Apr. 10, 2009) - New research from Trinity College Dublin published in this month's Annals of Surgery points to a potentially significant advance in the treatment of patients undergoing major cancer surgery. The study was carried out by the oesophageal research group at Trinity College Dublin and St James's Hospital. A randomised controlled trial showed omega-3 fatty acids given as part of an oral nutritional supplement resulted in the preservation of muscle mass in patients undergoing surgery for oesopahageal cancer, a procedure normally associated with significant weight loss and quality of life issues.

"Results indicated that mice on diets supplemented with flaxseed meal and flaxseed oil had, on average, 45 percent fewer tumors in the small intestine and the colon compared to the control group." The scientists published their research findings in February in the academic peer-reviewed international journal Nutrition and Cancer.